

Substitute for form 1449A/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				Application Number	10/597,304
				Filing Date	July 19, 2006
				First Named Inventor	John P. Morseman
				Art Unit	1628
				Examiner Name	Jennifer M. Kim
Sheet	1	of	1	Attorney Docket Number	2997-74-PUS

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number-kind Code <sup>2 (if known)</sup>	Publication Date MM-DD-YYYY	Name of Patentee of Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> ; Number <sup>4</sup> ; Kind Code <sup>5 (if known)</sup>	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>

OTHER ART (Including Author, Title, Date, Pertinent Pages, etc.)		
Examiner Initials*	Cite No. <sup>1</sup>	
	1	COSTA, E. et al., "Dendritic spine hypoplasticity and downregulation of reelin and GABAergic tone in schizophrenia vulnerability," Neurobiology of Disease, Blackwell Scientific Publications, Oxford, GB, Vol. 8, No. 5, Oct. 1, 2001, pp. 723-742
	2	PEET MALCOLM, "Eicosapentaenoic acid in the treatment of schizophrenia and depression: Rationale and preliminary double-blind clinical trial results," Prostaglandins Leukotrienes and Essential Fatty Acids, Vol. 69, No. 6, Dec. 2003, pp. 477-485

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference is considered, whether or not citation is in conformance and not considered. Include copy of this form with next communication to applicant.